Rakuten Aspyrian Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$351.8M
Industry:Biotech
Founded:N/A
Lead Investor(s):SBI Group, Rakuten

City Ranking

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Rakuten Aspyrian's estimated annual revenue is currently $31M per year.
  • Rakuten Aspyrian received $134.0M in venture funding in December 2018.
  • Rakuten Aspyrian's estimated revenue per employee is $155,000
  • Rakuten Aspyrian's total funding is $351.8M.

Employee Data

  • Rakuten Aspyrian has 200 Employees.
  • Rakuten Aspyrian grew their employee count by 12% last year.
  • Rakuten Aspyrian currently has 19 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
DiaCarta
$7M4510%N/A-N/A
Geron Corporati...
N/A205N/AN/A-N/A
Rigel Pharmaceu...
$46.8M3024%N/A-N/A
Althea Technolo...
$22.3M144N/AN/A-N/A
INOVA Diagnosti...
$44.3M286N/AN/A-N/A
10X Genomics
$101.2M65346%N/A-N/A
ProTrials Resea...
$33.3M2153%N/A-N/A
Advanced Cell D...
$28.7M1858%N/A-N/A
The J. Craig Ve...
$39.4M254N/AN/A-N/A
CellMax Life
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Rakuten Aspyrian, Inc., is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany. Since 2013, Rakuten Aspyrian has been developing new anticancer therapies based on the Photoimmunotherapy platform. Rakuten Aspyrian plans to become a fully integrated biopharma with research, development, and world-wide commercialization of therapies based on the Photoimmunotherapy platform. Our long-term objective is to commercialize a number of therapies based on Photoimmunotherapy to treat a broad range of solid tumor types as single agent and in combination with other immunomodulatory agents to generate robust and long lasting anticancer immunological responses. Rakuten Aspyrian is currently sponsoring a global Phase 3 multicenter clinical study for ASP-1929 to evaluate the efficacy and safety of ASP-1929 in patients with recurrent Head and Neck Cancer and additional Phase 2 studies to evaluate the safety and efficacy of ASP-1929 in patients with other cancer types. Given the rapid progression of the clinical studies, we are quickly expanding the team to support late stage pivotal clinical development and future commercialization of our products.

keywords:N/A

200

Number of Employees

$31M

Revenue (est)

19

Current Jobs

12%

Employee Growth %

$351.8M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Rakuten Aspyrian News

03/01/2019 - Rakuten Aspyrian Announces Name Change to Rakuten ...

SAN MATEO, Calif., March 1, 2019 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer ...

12/20/2018 - Rakuten Aspyrian Closes $284 Million Series C Financing for ...

SAN FRANCISCO, Dec. 20, 2018 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer ...

12/17/2018 - Rakuten Aspyrian Enrolling Phase 3 Trial of ASP-1929 for ...

SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies ...

Rakuten Aspyrian Funding

DateAmountRoundLead InvestorsReference
2018-08-24$150.0MCRakuten IncArticle
2018-12-21$134.0MCSBI GroupArticle

Rakuten Aspyrian Executive Hires

DateNameTitleReference
2018-11-15Mickey MikitaniCEO, chairmanArticle